← Back to patent-cliff list
177Lu-FAP-2286
Tier C — Watch / trade177Lu-FAP-2286
3B Pharmaceuticals GmbH
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：FAP
Indications (approved)：Solid tumour
Regional status
US
Phase II
2021-07-30
EU
Phase II
2021-07-30
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 177Lu-FAP-2286?
Approved indications include: Solid tumour.
When does the 177Lu-FAP-2286 patent expire?
No public expiry year is available for 177Lu-FAP-2286 yet; this page updates once verified.
How do I get a quote for 177Lu-FAP-2286 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06